YAP1 and neoplasm: Yamazoe et al. find that inhibition of YAP enhances sensitivity to ROS1-TKI lorlatinib and induces apoptosis in ROS1-rearranged KTOR71 NSCLC cells, and that combination therapy with YAP inhibitor verteporfin and lorlatinib suppresses tumor regrowth in vivo [84].